William Blair analyst Ryan Daniels has maintained their neutral stance on AGL stock, giving a Hold rating on October 31.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ryan Daniels has given his Hold rating due to a combination of factors surrounding Agilon Health’s recent performance and future outlook. The company’s third-quarter results were mixed, with total sales slightly surpassing expectations, but adjusted EBITDA falling significantly short of the consensus target. Membership numbers also came in below expectations, indicating some challenges in growth.
Despite these setbacks, there are positive developments, such as the reestablishment of full-year guidance and anticipated cost reductions from transformation initiatives. The company has also reduced its Part D exposure and improved its data aggregation capabilities, which could stabilize earnings in the future. However, the current financial metrics and uncertainties in risk adjustment revenue contribute to a cautious outlook, warranting a Hold rating.
Daniels covers the Healthcare sector, focusing on stocks such as Idexx Laboratories, TransMedics Group, and Addus Homecare. According to TipRanks, Daniels has an average return of 8.5% and a 50.31% success rate on recommended stocks.
In another report released on October 31, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $1.00 price target.